Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2007
Business Context: The registrant is a Nevada corporation with principal executive offices in Jerusalem, Israel, focused on the development of products for the treatment of diabetes mellitus.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document reports a specific contractual agreement rather than periodic financial performance.
Material Changes and Agreements
Item 1.01: Entry into a Material Definitive Agreement
- Counterparty: Encorium Group Inc. ("Encorium").
- Subject: Development of the Company's product for the treatment of diabetes mellitus.
- Compensation Structure: Encorium will be paid an hourly fee ranging from US $283 to US $450, dependent on the level of expertise of the medical personnel.
- Additional Costs: The Company will cover out-of-pocket expenses incurred by Encorium.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future financial performance, or a discussion of specific risks and contingencies beyond the execution of the development proposal. The primary focus is the formalization of the development partnership.
Investor Verification Checklist
- Verify the total estimated cost and duration of the proposal with Encorium Group Inc.
- Confirm the specific scope of work and deliverables defined in the attached proposal (Exhibit 10.1).
- Review the Company's cash position in recent 10-Q or 10-K filings to assess the ability to fund the hourly fees and out-of-pocket expenses.
- Check for any subsequent filings regarding the progress or termination of this agreement.